Compare INVE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | ONCY |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 98.7M |
| IPO Year | 1997 | 2002 |
| Metric | INVE | ONCY |
|---|---|---|
| Price | $2.60 | $0.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.50 | ★ $7.33 |
| AVG Volume (30 Days) | 131.8K | ★ 1.7M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | $2,505.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.43 | $0.71 |
| 52 Week High | $5.30 | $1.51 |
| Indicator | INVE | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 22.40 | 56.21 |
| Support Level | N/A | $0.90 |
| Resistance Level | $3.75 | $1.18 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 10.18 | 72.78 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.